Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Life-science tools, instruments and laboratory services / Analytical and characterisation instruments / Discovery-stage molecular and proteomics characterisation platforms

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Discovery-stage molecular and proteomics characterisation platforms

Analytical and characterisation instruments bought by discovery-stage biotechnology and pharmaceutical companies, and by discovery research groups within contract research organisations, to identify and quantify molecules, proteins and metabolites and to characterise biological pathways during target and compound screening. Excludes instruments bought primarily for release testing, clinical diagnostics or regulated manufacturing quality control.

Market size
—
Not sized yet
Growth
—
CAGR
Attractiveness
70 /100
for B2B sellers
Evidence
not sized
1 source · no estimate
Level
Niche
Segmented by
Customer type
Buyers
Discovery-stage biotechnology and pharmaceutical companies; discovery research units in contract research organisations
Buying centre
Head of discovery biology or bioanalytics, supported by research scientists, bioinformatics and procurement; strategic platform and budget approval typically sits with the research and development leader
Buying triggers
  • New drug-discovery programme or target-validation campaign
  • Need to identify biomarkers or pathway readouts for a new indication
  • Replacement of an ageing or unsupported instrument platform
  • Shift toward label-free or high-throughput molecular profiling
Pains
  • Screening campaigns generate large sample volumes with inconsistent cross-batch reproducibility
  • Capital instrument cost and long sample-preparation workflows limit the number of experiments run
  • Data formats and instrument software do not integrate with the buyer's analysis pipeline
  • Failure to obtain an early biomarker signal causes costly programme attrition
Scores (1–5)
Pain intensity4
Purchasing power3
Reachability3
Growth4

How this was sized

Not sized yet

No source provides a revenue pool for this buyer-defined niche. Indicative arithmetic only: global life science instrumentation revenue of USD 62.5 billion in 2025 [8] multiplied by an assumed 30% share for mass spectrometry, chromatography and spectroscopy used in discovery applications gives USD 18.75 billion, then by an assumed 45% share for discovery-stage biotechnology, pharmaceutical and contract research buyers gives USD 8.44 billion (18.75 x 0.45). Bottom-up, Low confidence: both allocation assumptions are unverified and the source's definition of instrumentation may not match the specified analytical and characterisation instrument scope.

Sources

Alongside it in Analytical and characterisation instruments

// Sell into Discovery-stage molecular and proteomics characterisation platforms

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.